AR033862A1 - Formulacion de medicamento que contiene un agente agonista muscarinico - Google Patents

Formulacion de medicamento que contiene un agente agonista muscarinico

Info

Publication number
AR033862A1
AR033862A1 ARP020100515A ARP020100515A AR033862A1 AR 033862 A1 AR033862 A1 AR 033862A1 AR P020100515 A ARP020100515 A AR P020100515A AR P020100515 A ARP020100515 A AR P020100515A AR 033862 A1 AR033862 A1 AR 033862A1
Authority
AR
Argentina
Prior art keywords
formulation containing
muscarinic agonist
medicinal formulation
agonist agent
talsaclidine
Prior art date
Application number
ARP020100515A
Other languages
English (en)
Inventor
Karoline Dr Bechtold-Peters
Thomas Friedl
Michael Dr Walz
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of AR033862A1 publication Critical patent/AR033862A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Formulación de medicamento que contiene talsaclidina 1', que consta de un núcleo que contiene la sustancia activa talsaclidina y un revestimiento de película que envuelve a éste núcleo.
ARP020100515A 2001-02-15 2002-02-15 Formulacion de medicamento que contiene un agente agonista muscarinico AR033862A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10106971A DE10106971A1 (de) 2001-02-15 2001-02-15 Arzneimittelformulierung die einen muskarinischen Agonisten enthält

Publications (1)

Publication Number Publication Date
AR033862A1 true AR033862A1 (es) 2004-01-07

Family

ID=7674095

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020100515A AR033862A1 (es) 2001-02-15 2002-02-15 Formulacion de medicamento que contiene un agente agonista muscarinico

Country Status (9)

Country Link
EP (1) EP1361871A2 (es)
JP (1) JP2004518710A (es)
AR (1) AR033862A1 (es)
AU (1) AU2002247705A1 (es)
CA (1) CA2434976A1 (es)
DE (1) DE10106971A1 (es)
MX (1) MXPA03007272A (es)
UY (1) UY27170A1 (es)
WO (1) WO2002064124A2 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY149356A (en) 2007-03-29 2013-08-30 Daiichi Sankyo Co Ltd Pharmaceutical composition
WO2010033045A1 (en) * 2008-09-16 2010-03-25 Igor Anatolievich Pomytkin Compositions and methods for prevention or treatment of beta amyloid deposition
KR101792299B1 (ko) 2010-03-19 2017-10-31 다이이찌 산쿄 가부시키가이샤 항응고제의 용출 개선 방법
TWI578988B (zh) 2011-08-10 2017-04-21 第一三共股份有限公司 含二胺衍生物之醫藥組成物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE8817121U1 (de) * 1988-11-22 1993-02-04 Boehringer Ingelheim Kg, 55218 Ingelheim Neue Quinuclidine
WO1998030243A1 (en) * 1997-01-08 1998-07-16 Warner-Lambert Company Acetylcholinesterase inhibitors in combination with muscarinic agonists for the treatment of alzheimer's disease
AU7247898A (en) * 1997-04-11 1998-11-11 Eli Lilly And Company Composition for treating pain
WO1998046225A1 (en) * 1997-04-11 1998-10-22 Eli Lilly And Company Method for treating schizophrenia
DE19851126A1 (de) * 1998-11-06 2000-05-11 Boehringer Ingelheim Pharma Verwendung von Talsaclidin zur Behandlung der Schizophrenie

Also Published As

Publication number Publication date
UY27170A1 (es) 2002-09-30
JP2004518710A (ja) 2004-06-24
WO2002064124A3 (de) 2002-12-05
CA2434976A1 (en) 2002-08-22
MXPA03007272A (es) 2003-12-04
EP1361871A2 (de) 2003-11-19
AU2002247705A1 (en) 2002-08-28
DE10106971A1 (de) 2002-08-29
WO2002064124A2 (de) 2002-08-22

Similar Documents

Publication Publication Date Title
PT1183014E (pt) Composicoes farmaceuticas orais de libertacao controlada e de dissimulacao de sabor
DE60019693D1 (de) Pharmazeutische zusammensetzungen, die wirkstoffabsorptionsfördernde verbindungen enthalten
FR2774288B1 (fr) Microgranules d'omeprazole gastroproteges, procede d'obtention et preparations pharmaceutiques
MA23608A1 (fr) Forme de dosage ii d'unite multiple en comprime
DE60335557D1 (de) Pharmazeutische zusammensetzungen enthaltend ein opioidanalgetikum
FR13C0057I2 (fr) Formulations d'aerosol a usage medical
CY1116429T1 (el) Υμενιο για δερματικη και διαδερμικη χορηγηση δραστικων συστατικων
ATE460921T1 (de) Medikamenthaltige zusammensetzung in aerosolform
ES2192226T3 (es) Composicion farmaceutica oral que contiene agentes activos antimicrobianos y pantoprazol de liberacion prolongada.
SE0003449D0 (sv) Anticancer compositions
MY112915A (en) Multiple unit tableted dosage form 1
PL337794A1 (en) Pharmaceutic agent for oral administration containing an active substance and cyclodextrin
BRPI0408655A (pt) formulações compreendendo um agente ativo e cacau em pó e a sua utilização
MA26491A1 (fr) Composes inhibiteurs selectifs de cox-2, anti-inflammatoires et compositions pharmaceutiques les contenant .
DE60142305D1 (de) Pharmazeutische zubereitung enthaltend n-ä2-(1,6,7,8-tetrahydro-2h-indenoä5,4 büfuran-8-yl)ethylüpropionamid ummantelt mit einer copolyvidon-enthaltenden, polyäthylenglykolfreien umhüllung
ATE240303T1 (de) 1,2,4-triazol-3-thion verbindungen
ES2113985T3 (es) Material de recubrimiento para formas medicamentosas de administracion oral.
AR033862A1 (es) Formulacion de medicamento que contiene un agente agonista muscarinico
DE60002089D1 (de) Niedrig dosierte tabletten, und verfahren zur herstellung
ATE158172T1 (de) Pulverförmige pharmazeutische zusammensetzung
PT1275383E (pt) Composicao farmaceutica de libertacao modificada que contem bupropion hc1 como substancia activa
JPH11279077A5 (es)
FR2826367B1 (fr) Nouveaux derives de [4-(4-cyanobenzoyl)phenyl] glycopyranoside, utilisation en tant que medicamment, procede d'obtention et compositions pharmaceutiques les contenant

Legal Events

Date Code Title Description
FA Abandonment or withdrawal